Neurizon and Clever Culture lead healthcare shares as trial funding and device orders lift sentiment

Neurizon and Clever Culture Systems were the week's biggest movers, each rising 35.71%. Neurizon gained after a multimillion-dollar NIH grant opened wider access to its experimental ALS treatment and after it appointed Dr Chris Bremer as chief executive. Clever Culture Systems advanced when Novo Nordisk ordered two more laboratory instruments. CONNEQT followed with a 23.53% rise after signing a US marketing deal for its Pulse heart-health monitor.

Trial funding drives biotech moves

Neurizon (ASX:NUZ) plans to give up to 200 US patients access to NUZ-001 for as long as 96 weeks. The NIH grant is expected to pay for the drug, manufacturing and certain regulatory costs. Investors valued the added patient data because it may provide longer-term safety, survival and biological information beside the main HEALEY ALS trial. Enrolment is targeted for the first quarter of calendar 2027. The plan can continue after the late second-quarter 2027 trial results only if those results are positive.

Neurizon also agreed to redeem US$1.15 million of convertible notes held by Obsidian. This reduces the notes held by Obsidian and pauses its share sales for two months. The company says it has enough money to complete the HEALEY ALS trial. The incoming chief executive, Dr Chris Bremer, starts on 1 October 2026. His licensing experience may help if the treatment produces useful trial results, but no commercial deal has been announced.

Manufacturing remains a key test

Immutep (ASX:IMM) rose 16.67% for the week, despite a failed TACTI-004 study. The company believes batches made at different factory sizes may not have been the same. It will make a new 200-litre batch and narrow its plans to PD-L1-negative head and neck cancer and soft tissue sarcoma. Replacement studies are not expected to start until the second half of 2027. The cause of the earlier difference is still unknown, so the plan depends on regulators, funding and a partner.

Medical-device companies also reported practical progress. EBR Systems (ASX:EBR) received ISO 13485 certification for its new Santa Clara factory. This quality certificate supports a planned fivefold rise in WiSE System production, subject to US approval. The US Food and Drug Administration also said the device did not need a recall after a cybersecurity incident. EBR found no evidence that patients or device performance were affected, but it continues to strengthen its computer controls.

OncoSil Medical (ASX:OSL) raised A$5.6 million from three large institutional investors. The money will support launches in the US and Australia after FDA and TGA approvals. Its contract manufacturer, Cyclotek, also secured ISO 13485 certification. Sydney production remains planned for the end of the second quarter of FY27, subject to another approval. The share price fell 6.70% for the week, showing that approval news has not yet removed concerns about sales and cash use.

Early gains did not always last

Clever Culture Systems (ASX:CC5) gained 35.71% after Novo Nordisk ordered two more APAS Independence machines. The order takes Novo Nordisk's total to three and includes software that connects the machines to its laboratory system. Formal testing is still needed before routine use. The shares continued higher after reopening at A$0.015, rising 26.67% from that price. That sustained buying suggests investors welcomed the chance of more orders from existing pharmaceutical customers.

CONNEQT Health (ASX:CQT) rose 23.53% after its Pulse monitor entered US longevity platform Blueprint's online marketplace. The deal gives CONNEQT another sales channel for its FDA-cleared device. However, the shares fell 4.55% after reopening at A$0.022. In simple terms, some of the early gain faded. The deal supports distribution, but the announcement did not disclose sales targets or guaranteed orders.

Evidence and use will decide the next moves

Cleo Diagnostics (ASX:COV) fell 18.18% after appointing Asuragen to run a US study of about 1,470 ovarian cancer samples. The study will measure how often the test finds disease correctly and how often it gives a correct clear result. Those results are intended to support a US 510(k) application in the first half of calendar 2027. The shares fell another 14.86% after reopening at A$0.37, creating an air pocket where selling continued rather than stabilising.

Emyria (ASX:EMD) reported FY26 revenue of A$4.05 million, up from A$1.39 million, and now has 18 beds across five operating or announced clinics. Its Sydney site is fitted out and is due to treat patients in September. The company also secured a speaking place at a 14 September FDA hearing on safe psychedelic-medicine delivery. The appearance may improve its profile, but it is not an FDA approval, funding award or commercial contract. The next tests are patient numbers, payments from insurers and use of the new clinics.

Arovella Therapeutics (ASX:ALA) released the first clinical batch of its off-the-shelf ALA-101 cell therapy and activated its first trial site at The Alfred. Patients are being screened, with dosing expected later this month. Prescient Therapeutics (ASX:PTX) extended its A$7 million share purchase plan to 15 September, with funds intended to support PTX-100 through a December 2026 review. EBOS Group (ASX:EBO) confirmed its NZD 0.63670588 final distribution and a NZD 20.47 reinvestment price. Its share price fell 2.96%.